Separately, Independent Research set a €15.50 ($18.02) target price on MediGene and gave the company a neutral rating in a report on Friday, August 10th.
MediGene stock traded up €0.08 ($0.09) during trading hours on Friday, hitting €10.91 ($12.69). The stock had a trading volume of 66,738 shares, compared to its average volume of 306,207. MediGene has a 1-year low of €8.53 ($9.92) and a 1-year high of €19.27 ($22.41).
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Featured Article: Compound Interest
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.